Gene Therapy Market Size to Cross $16.5 Billion by 2035 | Exclusive Report by Roots Analysis

The global gene therapy market size was valued at USD 2.4 billion in 2024 and likely to cross over USD 16.5 billion by 2035, growing at a CAGR of 19.25% during the forecast period 2024 to 2035

Gene therapies are a class of biologic products designed to alter the genetic material of an individual to treat rare diseases caused by inherited genetic mutations. These therapies are developed to address the underlying genetic cause of a disease, either by introducing a healthy version of the mutated gene or by inactivating the functions of disease-causing genes within the body. Currently, 20 gene therapies are commercially available for the treatment of various genetic disorders, including spinal muscular atrophy and sickle cell disease. Additionally, more than 370 candidates are currently being evaluated across various phases of clinical trials and around 920 gene therapies are being developed across preclinical and discovery stages of development. Further, it is worth highlighting that these therapies have demonstrated tremendous potential in revolutionizing the treatment of chronic conditions, with promising results in achieving complete disease remission. As such, the demand for gene therapies is increasing substantially, thereby encouraging gene therapy companies and non-industry players to enhance their R&D capabilities in order to develop and advance a greater number of therapies towards the commercial market. Driven by the growing demand for targeted therapies, the gene therapy market size is poised to experience a noteworthy increase during the forecast period.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/gene-therapy-market-3rd-edition-2019-2030/request-sample.html

By Therapeutic Area, muscle disorders are anticipated to capture the largest share of the global gene therapy market

1. The muscle disorders segment captures the largest revenue share of more than 70% in the gene therapy market, in 2024.
2. The cardiovascular disorders segment is anticipated to witness the highest market growth rate of 47.98%, during the forecast period.

By Type of Vector, Adeno-associated virus vector is anticipated to capture the largest share of the global gene therapy market

1. Adeno-associated virus vectors segment captures the largest revenue share of close to 80% in the gene therapy market, in 2024.
2. Non-viral vectors segment is anticipated to be the fastest growing segment in gene therapy market with a CAGR of 73.26%, during the forecast period.

By Type of Therapy, Gene Augmentation are anticipated to capture the largest share of the global gene therapy market

1. The gene augmentation segment captures the largest revenue share of 94% in the gene therapy market, in 2024.
2. The gene regulation segment is anticipated to witness a higher CAGR of 53.10%, during the forecast period.

By Type of Gene Delivery Method, In vivo gene delivery segment is anticipated to capture the largest share of the global gene therapy market

1. The in vivo gene delivery segment captures the largest revenue share of 91% in the gene therapy market, in 2024.
2. The ex vivo gene delivery segment is anticipated to witness the highest market growth rate of 30.67%, during the forecast period.

By Route of Administration, intravenous segment is anticipated to capture the largest share of the global gene therapy market

1. The intravenous route segment captures the largest revenue share of close to 85% in the gene therapy market, in 2024.
2. The intramuscular route segment is anticipated to witness a higher market growth rate of 31.98%, during the forecast period.

To request quote of this report, please visit
https://www.rootsanalysis.com/reports/gene-therapy-market-3rd-edition-2019-2030/request-quote.html

Gene Therapy Market - Regional Analysis

1. North America dominates the gene therapy market and accounts for the largest revenue share of more than 60% in 2024.
2. In Europe, the gene therapy market is anticipated to witness a higher growth rate of 20.79%, during the forecast period.

Key Companies Profiled

The gene therapy market report also includes profiles of key players (listed below) that are involved in the development of gene therapies:

1. Amgen
2. Artgen Biotech
3. BioMarin Pharmaceutical
4. bluebird bio
5. CRISPR Therapeutics
6. CSL Behring
7. Ferring Pharmaceuticals
8. Kolon TissueGene
9. Krystal Biotech
10. Novartis
11. Orchard Therapeutics
12. Pfizer
13. PTC Therapeutics
14. Sarepta Therapeutics
15. Shanghai Sunway Biotech
16. Sibiono GeneTech
17. Spark Therapeutics

Gene Therapy Market - Key Segments

Gene Therapy Market, by Therapeutic Area

1. Cardiovascular Disorders
2. Dermatological Disorders
3. Genetic Disorders
4. Hematological Disorders
5. Metabolic Disorders
6. Muscle Disorders
7. Oncological Disorders
8. Ophthalmic Disorders
9. Other Disorders

Gene Therapy Market, by Type of Vector

1. Adeno-Associated Virus Vectors
2. Adenovirus Vectors
3. Herpes Simplex Virus Vectors
4. Lentivirus Vectors
5. Non-Viral Vectors
6. Retroviral Vectors
7. Other Vectors

Gene Therapy Market, by Type of Therapy
1. Gene Augmentation
2. Gene Editing
3. Gene Regulation
4. Oncolytic Immunotherapy
5. Other Therapies

Gene Therapy Market, by Type of Gene Delivery Method
1. In vivo
2. Ex vivo

Gene Therapy Market, by Route of Administration
1. Intramuscular Route
2. Intratumoral Route
3. Intravenous Route
4. Subretinal Route
5. Other Routes of Administration

Gene Therapy Market, by Geographical Region
1. North America
2. Europe
3. Asia
4. Latin America
5. Rest of the World

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/gene-therapies-market/268.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.